Bradbury, C., Buckley, T., Sun, Y. Z., Rose, P., & Fitzmaurice, D. (2019). Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial. EClinicalMedicine.
Chicago Stili AlıntıBradbury, Charlotte, Tracey Buckley, Yong Zhong Sun, Peter Rose, ve David Fitzmaurice. "Patients With High Levels of Circulating Endothelial Progenitor Cells (EPC) Following At Least Three Months of Anticoagulation for Unprovoked Venous Thromboembolism (VTE) Are At Low Risk of Recurrent VTE—Results From the ExACT Randomised Controlled Trial." EClinicalMedicine 2019.
MLA AlıntıBradbury, Charlotte, et al. "Patients With High Levels of Circulating Endothelial Progenitor Cells (EPC) Following At Least Three Months of Anticoagulation for Unprovoked Venous Thromboembolism (VTE) Are At Low Risk of Recurrent VTE—Results From the ExACT Randomised Controlled Trial." EClinicalMedicine 2019.